Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam Target-Controlled Infusion System Accuracy Evaluation
ChiCTR2200063273Phase 4Not yet recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in procedural sedation and analgesia (PSA) (2 arms), sponsored by Peking University Shenzhen Hospital. Primary endpoints: Effect compartment transport rate constant (ke0) and System execution error of TCI remimazolam. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
procedural sedation and analgesia (PSA)
Beyond the preview
Go deeper on ChiCTR2200063273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063273.